AKT1 and plasma cell myeloma: But one major weakness of mTORC1/C2 inhibitor treatment is that it induces upregulation of IGF-1 receptor phosphorylation in MM cell lines, which rescues myeloma cells from apoptosis despite mTOR kinase inhibition and mTORC2/AKT blockage [47].